Comprehensive insights in GRK4 and hypertension: From mechanisms to potential therapeutics
Pharmacology & Therapeutics, ISSN: 0163-7258, Vol: 239, Page: 108194
2022
- 9Citations
- 4Usage
- 15Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef6
- Usage4
- Abstract Views4
- Captures15
- Readers15
- 15
Review Description
G protein-coupled receptors (GPCRs) mediate cellular responses to diverse extracellular stimuli that play vital roles in the regulation of biology, including behavior. Abnormal G protein-coupled receptor kinase (GRK)-mediated regulation of GPCR function is involved in the pathogenesis of hypertension. Among the seven GRK subtypes, GRK4 has attracted attention because of its constitutive activity and tissue-specific expression. Increasing number of studies show that GRK4 affects blood pressure by GPCR-mediated regulation of renal and arterial function. The target receptor of GRK4 is confined not only to GPCRs, but also to other blood pressure-regulating receptors, such as the adiponectin receptor. Genetic studies in humans show that in several ethnic groups, GRK4 gene variants (R65L, A142V, and A486V) are associated with salt-sensitive or salt-resistant essential hypertension and blood pressure responses to antihypertensive medicines. In this article, we present a comprehensive overview of GRK-mediated regulation of blood pressure, focusing on the latest research progress on GRK4 and hypertension and highlighting potential and novel strategies for the prevention and treatment of hypertension.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0163725822000882; http://dx.doi.org/10.1016/j.pharmthera.2022.108194; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85129736360&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/35487286; https://linkinghub.elsevier.com/retrieve/pii/S0163725822000882; https://hsrc.himmelfarb.gwu.edu/gwhpubs/740; https://hsrc.himmelfarb.gwu.edu/cgi/viewcontent.cgi?article=1739&context=gwhpubs; https://dx.doi.org/10.1016/j.pharmthera.2022.108194
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know